Dual Chamber Versus Single Chamber Cardiac Pacing in People 80 Years of Age and Older

NCT ID: NCT00116987

Last Updated: 2015-06-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

800 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-08-31

Study Completion Date

2009-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Of the 19,000 pacemakers implanted across Canada in 2002, 1/3 of them were for patients 80 years and older. This is the fastest growing segment of our population, yet no study has specifically been done in this age group to determine the optimal pacing mode.

We wish to determine whether dual chamber or single chamber pacing is associated with a reduction in emergency room visits or hospitalizations for cardiovascular causes (e.g., congestive heart failure (CHF), atrial fibrillation (AF)) resulting in improved quality of life.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Many patients who are 80 years of age and older, develop AF or CHF. Physiologic pacing has been shown to prevent AF compared to ventricular pacing. Whether prevention of AF and CHF by physiologic pacing reduces emergency room visits or hospitalizations for cardiovascular causes in this population in unknown.

The investigators wish to determine the optimal pacing mode for this patient population that would enable optimal management of cardiovascular problems, resulting in improved quality of life and minimizing use of health care facilities.

Patients recruited to the study will be randomized to either DDDR or VVIR pacing, and followed in the clinic every 6 months for the 3 years of the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Cardiac Pacing, Artificial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Physiologic pacemakers usually have two leads - one positioned in the right atrium (upper heart chamber) and one positioned in the right ventricle.

Group Type OTHER

Dual chamber cardiac pacemaker

Intervention Type DEVICE

Physiologic pacemakers usually have two leads - one positioned in the right atrium (upper heart chamber) and one positioned in the right ventricle.

2

Ventricular pacemakers have a single lead (wire) positioned in the right ventricle (lower pumping chamber) to sense and pace the ventricle.

Group Type OTHER

Single chamber cardiac pacemaker

Intervention Type DEVICE

Ventricular pacemakers have a single lead (wire) positioned in the right ventricle (lower pumping chamber) to sense and pace the ventricle.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dual chamber cardiac pacemaker

Physiologic pacemakers usually have two leads - one positioned in the right atrium (upper heart chamber) and one positioned in the right ventricle.

Intervention Type DEVICE

Single chamber cardiac pacemaker

Ventricular pacemakers have a single lead (wire) positioned in the right ventricle (lower pumping chamber) to sense and pace the ventricle.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 80 years of age and older
* Symptomatic bradycardia

Exclusion Criteria

* Permanent atrial fibrillation
* Previous pacemaker implant
* Life expectancy less than 1 year
* Geographic isolation
* Unable to give informed consent
Minimum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Calgary Health Trust

OTHER

Sponsor Role collaborator

University of Calgary

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr. Anne M. Gillis

Professor of Medicine, University of Calgary

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anne M Gillis, MD

Role: PRINCIPAL_INVESTIGATOR

Director of Pacing and Electrophysiology, Professor of Medicine, University of Calgary

Derek V Exner, MD, MPH

Role: STUDY_DIRECTOR

University of Calgary

D. George Wyse, MD, PhD

Role: STUDY_DIRECTOR

University of Calgary

L. Brent Mitchell, MD

Role: STUDY_DIRECTOR

University of Calgary

Robert S Sheldon, MD, Ph D

Role: STUDY_DIRECTOR

University of Calgary

John M Rothschild, MD

Role: STUDY_DIRECTOR

University of Calgary

Henry J Duff, MD

Role: STUDY_DIRECTOR

University of Calgary

John Burgess, MD

Role: STUDY_DIRECTOR

University of Calgary

Alexander Bayes, MD

Role: STUDY_DIRECTOR

University of Calgary

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Calgary

Calgary, Alberta, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

17096

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

SQ-Kyrin-T First-in-man Feasibility Study
NCT06605313 ACTIVE_NOT_RECRUITING NA